Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (8): 1385-1388.doi: 10.3969/j.issn.1673-8225.2011.08.013

Previous Articles     Next Articles

Drug loading properties, cell uptake and cytotoxicity of new peptide polyamidoamine targeting drug carrier

Feng Li-na1, Liu Jin-jian1, Chu Li-ping1, Yang Cui-hong2, Wang De-zhi1, Zhang Chun-ming1, Liu Jian-feng1,2
  

  1. 1Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin  300192, China
    2Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Science, Nankai University, Tianjin   300071, China
  • Received:2010-11-04 Revised:2010-11-25 Online:2011-02-19 Published:2011-02-19
  • Contact: Liu Jian-feng, Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China; Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Science, Nankai University, Tianjin 300071, China lewis78@163.com
  • About author:Feng Li-na★, Studyiny for master’s degree, Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China
  • Supported by:

    the National Natural Science Foundation of China, No. 30700178*; Tianjin Natural Science Foundation, No. 09JCYBJC13400*; the Development Foundation of the Institute of Radiation Medicine, No. SF0627*, SF0823*, ST1011*

PDF

571

Abstract:

BACKGROUND: Previous study screened a peptide (lung cancer targeting peptide, LCTP) which could bind NCI-H460 non-small cell lung cancer (NSCLC) by phage display in vivo. LCTP was combined with modified polyamidoamine (PAMAM) dendritic polymers to prepare nano-targeting drug carrier, PAMAM-Ac-FITC-LCTP. It had good targeting capability to NSCLC in vitro and in vivo.
OBJECTIVE: To further study the PAMAM-Ac-FITC-LCTP as a targeting carrier on encapsulation, release, cell uptake, and toxicity properties of doxorubicin (DOX) based on previous research.
METHODS: Taking screened peptide LCTP as targeting agent, PAMAM-Ac-FITC-LCTP targeting carrier was constructed. PAMAM-Ac-FITC-LCTP was combined with DOX using physical encapsulation method. The carrier on release function of drug was observed by dialysis experiment in vitro. Confocal microscopy was used to observe cells uptake of the PAMAM-Ac-FITC-LCTP/DOX. Free DOX as controls, the effect of carrier on NCI-H460 cells was observed with MTT assay after the drug carrier.
RESULTS AND CONCLUSION: The maximum encapsulation rate of PAMAM-Ac-FITC-LCTP to DOX was 7.46%. The carrier had obvious sustained release effect on DOX, and ion concentration, pH and temperature could affect DOX release. It is indicated that PAMAM-Ac-FITC-LCTP could combined with DOX by electrostatic interaction. PAMAM-Ac-FITC-LCTP/DOX was more efficient than individual drugs into NCI-H460 cells in a short period of time; however, the 24-hour cytotoxicity of complex was similar with DOX. These results suggest that PAMAM-Ac-FITC-LCTP might be a useful drug carrier for cancer treatment and clinical diagnosis.

CLC Number: